Focused On-demand Library for Transmembrane channel-like protein 1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q8TDI8

UPID:

TMC1_HUMAN

Alternative names:

Transmembrane cochlear-expressed protein 1

Alternative UPACC:

Q8TDI8; A8MVZ2; B1AM91

Background:

Transmembrane channel-like protein 1, also known as Transmembrane cochlear-expressed protein 1, plays a crucial role in the auditory system. It is a probable ion channel essential for the normal function of cochlear hair cells, which are pivotal for hearing. This protein's malfunction is linked to sensorineural hearing loss, a condition resulting from damage to the inner ear or nerve pathways.

Therapeutic significance:

The protein is implicated in two forms of hearing loss: Deafness, autosomal dominant, 36, and Deafness, autosomal recessive, 7. Both conditions underscore the protein's critical role in auditory health. Understanding the role of Transmembrane channel-like protein 1 could open doors to potential therapeutic strategies for these hearing impairments.